These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The emerging role of miR-200 family in metastasis: focus on EMT, CSCs, angiogenesis, and anoikis. Babaei G; Raei N; Toofani Milani A; Gholizadeh-Ghaleh Aziz S; Pourjabbar N; Geravand F Mol Biol Rep; 2021 Oct; 48(10):6935-6947. PubMed ID: 34510322 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological strategies and micrometastasis: what is known? What must be done? Perret GY Minerva Med; 2010 Jun; 101(3):163-78. PubMed ID: 20562804 [TBL] [Abstract][Full Text] [Related]
4. Critical determinants of cancer metastasis: rationale for therapy. Fidler IJ Cancer Chemother Pharmacol; 1999; 43 Suppl():S3-10. PubMed ID: 10357552 [TBL] [Abstract][Full Text] [Related]
5. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. Kauffman EC; Robinson VL; Stadler WM; Sokoloff MH; Rinker-Schaeffer CW J Urol; 2003 Mar; 169(3):1122-33. PubMed ID: 12576866 [TBL] [Abstract][Full Text] [Related]
6. The challenge of targeting metastasis. Fidler IJ; Kripke ML Cancer Metastasis Rev; 2015 Dec; 34(4):635-41. PubMed ID: 26328524 [TBL] [Abstract][Full Text] [Related]
7. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Iiizumi M; Liu W; Pai SK; Furuta E; Watabe K Biochim Biophys Acta; 2008 Dec; 1786(2):87-104. PubMed ID: 18692117 [TBL] [Abstract][Full Text] [Related]
9. Targeting anoikis resistance in prostate cancer metastasis. Sakamoto S; Kyprianou N Mol Aspects Med; 2010 Apr; 31(2):205-14. PubMed ID: 20153362 [TBL] [Abstract][Full Text] [Related]
10. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Liu W; Vivian CJ; Brinker AE; Hampton KR; Lianidou E; Welch DR Cancer Microenviron; 2014 Dec; 7(3):117-31. PubMed ID: 24938990 [TBL] [Abstract][Full Text] [Related]
11. New pharmacological strategies against metastatic spread. Perret GY; Crépin M Fundam Clin Pharmacol; 2008 Oct; 22(5):465-92. PubMed ID: 18844722 [TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene. Popescu NC; Goodison S Mol Diagn Ther; 2014 Jun; 18(3):293-302. PubMed ID: 24519699 [TBL] [Abstract][Full Text] [Related]
13. The role of tumor metastasis suppressors in cancers of breast and prostate. Furuta E; Bandyopadhyay S; Iiizumi M; Mohinta S; Zhan R; Watabe K Front Biosci; 2006 Sep; 11():2845-60. PubMed ID: 16720356 [TBL] [Abstract][Full Text] [Related]
14. Development and prevention of metastasis. Kohn EC Anticancer Res; 1993; 13(6B):2553-9. PubMed ID: 7510940 [TBL] [Abstract][Full Text] [Related]
15. Anti-invasive/anti-metastasis strategies: new roads, new tools and new hopes. Dollé L; Depypere HT; Bracke ME Curr Cancer Drug Targets; 2006 Dec; 6(8):729-51. PubMed ID: 17168676 [TBL] [Abstract][Full Text] [Related]
16. Current and future approaches for the therapeutic targeting of metastasis (review). Germanov E; Berman JN; Guernsey DL Int J Mol Med; 2006 Dec; 18(6):1025-36. PubMed ID: 17089005 [TBL] [Abstract][Full Text] [Related]
18. The receptor tyrosine kinases: role in cancer progression. Lamorte L; Park M Surg Oncol Clin N Am; 2001 Apr; 10(2):271-88, viii. PubMed ID: 11382587 [TBL] [Abstract][Full Text] [Related]